Lyka Labs Limited has informed the Exchange regarding a press release dated April 08, 2025, titled "Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the LODR) Pursuant to the Regulation 30 and other applicable provisions of the LODR, we are pleased to inform you that Company has been granted a patent for Indian Patent for its proprietary product, Pregabalin Gel 8% by Patent Office India. ".
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lyka Labs Limited has announced that the Patent Office India has granted an Indian patent for the company's proprietary product, Pregabalin Gel 8%. The intimation was made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements, 2015. A patent grant gives the company exclusive rights to manufacture and commercialize this formulation in India for the patent's duration. This strengthens the company's intellectual property portfolio and could provide a competitive edge in the market for this product.
Positive for shareholders — the patent grant protects the product from generic competition and could support future revenue and pricing power. However, the direct impact on stock price depends on the product's contribution to overall sales.